| NCT04092270 |
A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients |
https://ClinicalTrials.gov/show/NCT04092270 |
Recruiting |
National Cancer Institute (NCI) |
2022-09-01 |
| NCT03775265 |
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03775265 |
Recruiting |
National Cancer Institute (NCI) |
2025-06-01 |
| NCT03737123 |
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03737123 |
Recruiting |
Hoosier Cancer Research Network |
2021-01-31 |
| NCT03502785 |
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03502785 |
Active, not recruiting |
Inovio Pharmaceuticals |
2021-07-31 |
| NCT03410693 |
Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03410693 |
Active, not recruiting |
Bayer |
2020-11-30 |
| NCT03409458 |
A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab |
https://ClinicalTrials.gov/show/NCT03409458 |
Recruiting |
Phosplatin Therapeutics |
2020-02-01 |
| NCT03407976 |
Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03407976 |
Active, not recruiting |
University of Utah |
2023-06-30 |
| NCT03390595 |
Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03390595 |
Active, not recruiting |
Associació per a la Recerca Oncologica, Spain |
2020-08-31 |
| NCT03389438 |
Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03389438 |
Recruiting |
Beijing Huanxing Cancer Hospital |
2020-01-31 |
| NCT03375307 |
Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects |
https://ClinicalTrials.gov/show/NCT03375307 |
Recruiting |
National Cancer Institute (NCI) |
2023-08-21 |
| NCT03374488 |
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03374488 |
Active, not recruiting |
Incyte Corporation |
2018-07-27 |
| NCT03361865 |
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) |
https://ClinicalTrials.gov/show/NCT03361865 |
Active, not recruiting |
Incyte Corporation |
2018-08-09 |
| NCT03317158 |
ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder |
https://ClinicalTrials.gov/show/NCT03317158 |
Recruiting |
Hoosier Cancer Research Network |
2022-09-01 |
| NCT03296306 |
Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03296306 |
Recruiting |
Asan Medical Center |
2021-08-31 |
| NCT03288545 |
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT03288545 |
Recruiting |
Astellas Pharma Inc |
2023-07-31 |
| NCT03287050 |
Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03287050 |
Active, not recruiting |
University of Michigan Rogel Cancer Center |
2019-03-13 |
| NCT03272217 |
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT03272217 |
Recruiting |
Hoosier Cancer Research Network |
2020-06-30 |
| NCT03266900 |
A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival |
https://ClinicalTrials.gov/show/NCT03266900 |
Recruiting |
University Health Network, Toronto |
2020-12-31 |
| NCT03265080 |
Expressing Personalized Tumor Antigens Study |
https://ClinicalTrials.gov/show/NCT03265080 |
Active, not recruiting |
Advaxis, Inc. |
2020-05-31 |
| NCT03263039 |
Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab |
https://ClinicalTrials.gov/show/NCT03263039 |
Recruiting |
Erasmus Medical Center |
2019-08-21 |
| NCT03240016 |
Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT03240016 |
Recruiting |
University of Michigan Rogel Cancer Center |
2021-10-01 |
| NCT03236935 |
Phase Ib of L-NMMA and Pembrolizumab |
https://ClinicalTrials.gov/show/NCT03236935 |
Recruiting |
The Methodist Hospital System |
2020-01-01 |
| NCT03230201 |
Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma) |
https://ClinicalTrials.gov/show/NCT03230201 |
Recruiting |
Peking University First Hospital |
2021-01-01 |
| NCT03228667 |
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT03228667 |
Recruiting |
Altor BioScience |
2021-06-30 |
| NCT03219775 |
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03219775 |
Recruiting |
AIO-Studien-gGmbH |
2020-12-31 |
| NCT03219333 |
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03219333 |
Active, not recruiting |
Astellas Pharma Inc |
2020-11-30 |
| NCT03209206 |
The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence |
https://ClinicalTrials.gov/show/NCT03209206 |
Recruiting |
Seoul National University Hospital |
2020-06-19 |
| NCT03185468 |
Intervention of Bladder Cancer by CAR-T |
https://ClinicalTrials.gov/show/NCT03185468 |
Recruiting |
Shenzhen Geno-Immune Medical Institute |
2019-12-31 |
| NCT03171493 |
Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy |
https://ClinicalTrials.gov/show/NCT03171493 |
Recruiting |
Vyriad, Inc. |
2020-12-31 |
| NCT03115801 |
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers |
https://ClinicalTrials.gov/show/NCT03115801 |
Active, not recruiting |
Weill Medical College of Cornell University |
2020-12-31 |
| NCT03113266 |
Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03113266 |
Recruiting |
Shanghai Junshi Bioscience Co., Ltd. |
2020-02-29 |
| NCT03093922 |
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03093922 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-03-31 |
| NCT03091660 |
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03091660 |
Recruiting |
Southwest Oncology Group |
2022-02-15 |
| NCT03081858 |
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03081858 |
Recruiting |
Lipac Oncology LLC |
2020-05-31 |
| NCT03070990 |
A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03070990 |
Completed |
Astellas Pharma Inc |
2019-02-25 |
| NCT03047213 |
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations |
https://ClinicalTrials.gov/show/NCT03047213 |
Recruiting |
National Cancer Institute (NCI) |
2022-10-01 |
| NCT03039413 |
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy |
https://ClinicalTrials.gov/show/NCT03039413 |
Active, not recruiting |
Thomas Jefferson University |
2021-03-15 |
| NCT03030157 |
Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03030157 |
Recruiting |
RenJi Hospital |
2020-01-31 |
| NCT02994758 |
Development of Diagnostics and Treatment of Urological Cancers |
https://ClinicalTrials.gov/show/NCT02994758 |
Recruiting |
Helsinki University Central Hospital |
2020-12-31 |
| NCT02989584 |
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer |
https://ClinicalTrials.gov/show/NCT02989584 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-12-31 |
| NCT02989064 |
MAGE-A10ᶜâ·â¹â¶T for Urothelial Cancer, Melanoma or Head and Neck Cancers |
https://ClinicalTrials.gov/show/NCT02989064 |
Active, not recruiting |
Adaptimmune |
2019-12-18 |
| NCT02986867 |
SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma |
https://ClinicalTrials.gov/show/NCT02986867 |
Completed |
University of Texas Southwestern Medical Center |
2018-03-07 |
| NCT02983045 |
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors ( PIVOT-02 ) |
https://ClinicalTrials.gov/show/NCT02983045 |
Active, not recruiting |
Nektar Therapeutics |
2020-12-31 |
| NCT02969083 |
Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT02969083 |
Recruiting |
The European Uro-Oncology Group |
2020-10-31 |
| NCT02968732 |
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder |
https://ClinicalTrials.gov/show/NCT02968732 |
Active, not recruiting |
Fox Chase Cancer Center |
2019-08-19 |
| NCT02951325 |
Bladder Cancer Adjuvant Radiotherapy Trial |
https://ClinicalTrials.gov/show/NCT02951325 |
Recruiting |
Tata Memorial Centre |
2023-04-13 |
| NCT02923739 |
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02923739 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2025-05-31 |
| NCT02923557 |
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT02923557 |
Recruiting |
Peking University First Hospital |
2021-11-30 |
| NCT02901548 |
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder |
https://ClinicalTrials.gov/show/NCT02901548 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2020-12-31 |
| NCT02897765 |
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer |
https://ClinicalTrials.gov/show/NCT02897765 |
Completed |
Neon Therapeutics, Inc. |
2020-02-29 |
| NCT02876861 |
Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUC |
https://ClinicalTrials.gov/show/NCT02876861 |
Recruiting |
Xiangya Hospital of Central South University |
2020-08-31 |
| NCT02872714 |
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) |
https://ClinicalTrials.gov/show/NCT02872714 |
Recruiting |
Incyte Corporation |
2020-08-31 |
| NCT02853305 |
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) |
https://ClinicalTrials.gov/show/NCT02853305 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2020-05-21 |
| NCT02845323 |
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder |
https://ClinicalTrials.gov/show/NCT02845323 |
Recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2020-09-30 |
| NCT02844816 |
Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer |
https://ClinicalTrials.gov/show/NCT02844816 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-04-01 |
| NCT02812420 |
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery |
https://ClinicalTrials.gov/show/NCT02812420 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-03-31 |
| NCT02808143 |
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer |
https://ClinicalTrials.gov/show/NCT02808143 |
Recruiting |
Northwestern University |
2020-01-31 |
| NCT02807636 |
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT02807636 |
Active, not recruiting |
Hoffmann-La Roche |
2021-06-11 |
| NCT02793128 |
The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study |
https://ClinicalTrials.gov/show/NCT02793128 |
Active, not recruiting |
UroGen Pharma Ltd. |
2019-04-05 |
| NCT02788201 |
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT02788201 |
Completed |
National Institutes of Health Clinical Center (CC) |
2019-10-23 |
| NCT02767921 |
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT02767921 |
Recruiting |
University of Southern California |
2020-08-02 |
| NCT02740426 |
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT02740426 |
Recruiting |
Peking University First Hospital |
2021-05-31 |
| NCT02717156 |
Combination Therapy With Pembrolizumab and sEphB4-HSA in Previously Treated Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT02717156 |
Recruiting |
University of Southern California |
2020-11-21 |
| NCT02710734 |
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) |
https://ClinicalTrials.gov/show/NCT02710734 |
Recruiting |
Fox Chase Cancer Center |
2021-04-30 |
| NCT02693717 |
Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT02693717 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-05-31 |
| NCT02665039 |
A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function |
https://ClinicalTrials.gov/show/NCT02665039 |
Completed |
Karolinska University Hospital |
2018-09-30 |
| NCT02662309 |
Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder |
https://ClinicalTrials.gov/show/NCT02662309 |
Active, not recruiting |
Queen Mary University of London |
2018-07-31 |
| NCT02657486 |
BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder |
https://ClinicalTrials.gov/show/NCT02657486 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-01-31 |
| NCT02643043 |
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch |
https://ClinicalTrials.gov/show/NCT02643043 |
Active, not recruiting |
Hoosier Cancer Research Network |
2020-01-31 |
| NCT02608125 |
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT02608125 |
Active, not recruiting |
Principia Biopharma Inc. |
2020-12-31 |
| NCT02607709 |
Lymphadenectomy in Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT02607709 |
Recruiting |
Zealand University Hospital |
2022-01-31 |
| NCT02585362 |
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program |
https://ClinicalTrials.gov/show/NCT02585362 |
Completed |
Kantonsspital Winterthur KSW |
2018-10-31 |
| NCT03138889 |
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03138889 |
Recruiting |
Nektar Therapeutics |
2021-06-30 |
| NCT02769962 |
Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT02769962 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2023-07-01 |
| NCT02647112 |
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT02647112 |
Active, not recruiting |
Nucleix Ltd. |
2020-12-31 |
| NCT02573259 |
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors |
https://ClinicalTrials.gov/show/NCT02573259 |
Active, not recruiting |
Pfizer |
2020-11-02 |
| NCT02502266 |
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02502266 |
Recruiting |
National Cancer Institute (NCI) |
2023-06-30 |
| NCT02443324 |
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02443324 |
Active, not recruiting |
Eli Lilly and Company |
2018-08-31 |
| NCT02567409 |
Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor M6620 in Treating Patients With Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT02567409 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-08-31 |
| NCT03988309 |
The Cxbladder Hematuria Clinical Utility Study |
https://ClinicalTrials.gov/show/NCT03988309 |
Recruiting |
Pacific Edge Limited |
2020-07-31 |
| NCT03547973 |
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT03547973 |
Recruiting |
Immunomedics, Inc. |
2021-09-30 |
| NCT03397394 |
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03397394 |
Completed |
Clovis Oncology, Inc. |
2019-12-12 |
| NCT03387761 |
Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy |
https://ClinicalTrials.gov/show/NCT03387761 |
Recruiting |
The Netherlands Cancer Institute |
2021-01-01 |
| NCT02535650 |
Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT02535650 |
Recruiting |
Samsung Medical Center |
2019-12-31 |
| NCT02500121 |
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer |
https://ClinicalTrials.gov/show/NCT02500121 |
Active, not recruiting |
Hoosier Cancer Research Network |
2019-07-01 |
| NCT02496208 |
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
https://ClinicalTrials.gov/show/NCT02496208 |
Recruiting |
National Cancer Institute (NCI) |
2020-09-30 |
| NCT02482168 |
Study of the CD40 Agonistic Monoclonal Antibody APX005M |
https://ClinicalTrials.gov/show/NCT02482168 |
Completed |
Apexigen, Inc. |
2018-06-13 |
| NCT02462239 |
Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging |
https://ClinicalTrials.gov/show/NCT02462239 |
Recruiting |
Ontario Clinical Oncology Group (OCOG) |
2020-04-30 |
| NCT02451423 |
Neoadjuvant Atezolizumab in Localized Bladder Cancer |
https://ClinicalTrials.gov/show/NCT02451423 |
Recruiting |
University of California, San Francisco |
2020-12-31 |
| NCT02450331 |
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection |
https://ClinicalTrials.gov/show/NCT02450331 |
Active, not recruiting |
Hoffmann-La Roche |
2019-11-30 |
| NCT02446600 |
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02446600 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-02-23 |
| NCT02438865 |
Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy. |
https://ClinicalTrials.gov/show/NCT02438865 |
Completed |
Mansoura University |
2018-05-01 |
| NCT02437370 |
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT02437370 |
Recruiting |
University of California, Davis |
2020-06-30 |
| NCT02426125 |
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT02426125 |
Active, not recruiting |
Eli Lilly and Company |
2017-04-21 |
| NCT02412670 |
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02412670 |
Active, not recruiting |
Eastern Cooperative Oncology Group |
2020-02-29 |
| NCT02364713 |
MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02364713 |
Recruiting |
Mayo Clinic |
2027-03-17 |
| NCT02351739 |
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer |
https://ClinicalTrials.gov/show/NCT02351739 |
Completed |
Acerta Pharma BV |
2018-02-28 |
| NCT02326909 |
Diagnostic Accuracy of Optical Coherence Tomography in Upper Urinary Tract Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT02326909 |
Completed |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2014-12-31 |
| NCT02318329 |
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02318329 |
Completed |
Five Prime Therapeutics, Inc. |
2019-02-28 |
| NCT02300610 |
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer |
https://ClinicalTrials.gov/show/NCT02300610 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2017-08-07 |
| NCT02236195 |
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes |
https://ClinicalTrials.gov/show/NCT02236195 |
Completed |
Mirati Therapeutics Inc. |
2016-04-30 |
| NCT02202772 |
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder |
https://ClinicalTrials.gov/show/NCT02202772 |
Active, not recruiting |
Columbia University |
2018-06-01 |
| NCT02160600 |
Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial |
https://ClinicalTrials.gov/show/NCT02160600 |
Completed |
All India Institute of Medical Sciences, New Delhi |
2016-12-31 |
| NCT02111941 |
Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy |
https://ClinicalTrials.gov/show/NCT02111941 |
Active, not recruiting |
Mayo Clinic |
2017-08-18 |
| NCT02109328 |
Alisertib in Chemotherapy-pretreated Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT02109328 |
Completed |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2015-07-02 |
| NCT02101931 |
A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine |
https://ClinicalTrials.gov/show/NCT02101931 |
Completed |
Princess Al-Johara Al-Ibrahim Cancer Research Center |
2016-03-31 |
| NCT02068794 |
MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02068794 |
Recruiting |
Mayo Clinic |
2021-03-10 |
| NCT02020707 |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers |
https://ClinicalTrials.gov/show/NCT02020707 |
Recruiting |
Mayo Clinic |
2020-10-03 |
| NCT04383938 |
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies |
https://ClinicalTrials.gov/show/NCT04383938 |
Recruiting |
Aprea Therapeutics |
2021-12-31 |
| NCT03854474 |
Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03854474 |
Recruiting |
National Cancer Institute (NCI) |
2020-06-30 |
| NCT02014337 |
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors |
https://ClinicalTrials.gov/show/NCT02014337 |
Completed |
Corcept Therapeutics |
2017-12-31 |
| NCT01993979 |
A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) |
https://ClinicalTrials.gov/show/NCT01993979 |
Active, not recruiting |
Institute of Cancer Research, United Kingdom |
2018-11-07 |
| NCT01954173 |
Adjuvant Radiation for High Risk Bladder Cancer |
https://ClinicalTrials.gov/show/NCT01954173 |
Recruiting |
Emory University |
2030-07-31 |
| NCT01878188 |
Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma |
https://ClinicalTrials.gov/show/NCT01878188 |
Completed |
Anchiano Therapeutics Israel Ltd. |
2015-10-31 |
| NCT01846520 |
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers |
https://ClinicalTrials.gov/show/NCT01846520 |
Completed |
City of Hope Medical Center |
2019-05-23 |
| NCT01844947 |
Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract |
https://ClinicalTrials.gov/show/NCT01844947 |
Completed |
Karolinska University Hospital |
2017-10-18 |
| NCT01824329 |
Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer |
https://ClinicalTrials.gov/show/NCT01824329 |
Completed |
University of Michigan |
2014-08-31 |
| NCT01801137 |
The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium |
https://ClinicalTrials.gov/show/NCT01801137 |
Completed |
Hopital Foch |
2014-10-31 |
| NCT01780545 |
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer |
https://ClinicalTrials.gov/show/NCT01780545 |
Completed |
Hoosier Cancer Research Network |
2017-10-31 |
| NCT01688999 |
Cabozantinib for Advanced Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT01688999 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2017-12-11 |
| NCT01668459 |
Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel |
https://ClinicalTrials.gov/show/NCT01668459 |
Completed |
University Hospital Birmingham NHS Foundation Trust |
2017-11-30 |
| NCT01642082 |
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer |
https://ClinicalTrials.gov/show/NCT01642082 |
Completed |
Gynecologic Oncology Group |
2016-01-31 |
| NCT01606345 |
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT01606345 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2016-04-30 |
| NCT01600339 |
A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) |
https://ClinicalTrials.gov/show/NCT01600339 |
Completed |
Rambam Health Care Campus |
2015-01-31 |
| NCT01599013 |
JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin |
https://ClinicalTrials.gov/show/NCT01599013 |
Completed |
Pierre Fabre Medicament |
2013-10-31 |
| NCT04322643 |
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT04322643 |
Recruiting |
Case Comprehensive Cancer Center |
2021-05-31 |
| NCT01551030 |
Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium |
https://ClinicalTrials.gov/show/NCT01551030 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-03-31 |
| NCT01529411 |
Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT01529411 |
Completed |
Spanish Oncology Genito-Urinary Group |
2013-02-28 |
| NCT01524991 |
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT01524991 |
Completed |
Hoosier Cancer Research Network |
2017-07-15 |
| NCT01520038 |
Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer |
https://ClinicalTrials.gov/show/NCT01520038 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2013-12-31 |
| NCT01495676 |
A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer |
https://ClinicalTrials.gov/show/NCT01495676 |
Recruiting |
Institut du Cancer de Montpellier - Val d’Aurelle |
2022-09-30 |
| NCT01490437 |
Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT01490437 |
Completed |
Asan Medical Center |
2013-12-31 |
| NCT01478685 |
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01478685 |
Completed |
Celgene |
2015-11-17 |
| NCT01440998 |
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer |
https://ClinicalTrials.gov/show/NCT01440998 |
Completed |
National Cancer Institute (NCI) |
2015-12-31 |
| NCT01437488 |
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy |
https://ClinicalTrials.gov/show/NCT01437488 |
Completed |
Thomas Jefferson University |
2014-08-04 |
| NCT01328574 |
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT01328574 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-05-31 |
| NCT04341740 |
Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT04341740 |
Recruiting |
University of Oklahoma |
2021-07-31 |
| NCT04264936 |
A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT04264936 |
Recruiting |
Beijing Cancer Hospital |
2021-01-30 |
| NCT04200963 |
IK-175 in Patients With Advanced or Metastatic Solid Tumors and Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT04200963 |
Recruiting |
Ikena Oncology |
2022-09-30 |
| NCT04198766 |
Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) |
https://ClinicalTrials.gov/show/NCT04198766 |
Recruiting |
Inhibrx, Inc. |
2022-12-02 |
| NCT04197986 |
Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations |
https://ClinicalTrials.gov/show/NCT04197986 |
Recruiting |
QED Therapeutics, Inc. |
2024-01-31 |
| NCT04197089 |
Biological Effect of Vitamin D in Patients With Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT04197089 |
Recruiting |
Germans Trias i Pujol Hospital |
2021-07-31 |
| NCT04173338 |
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT04173338 |
Recruiting |
Augusta University |
2020-11-30 |
| NCT04167631 |
Can VI-RADS/ADC Accurately Stage Bladder Cancer?? |
https://ClinicalTrials.gov/show/NCT04167631 |
Active, not recruiting |
Mansoura University |
2020-06-01 |
| NCT04113603 |
Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography |
https://ClinicalTrials.gov/show/NCT04113603 |
Recruiting |
Chang Gung Memorial Hospital |
2021-07-31 |
| NCT04099589 |
Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT04099589 |
Recruiting |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2022-10-01 |
| NCT04077359 |
Prospective Trial for Examining Hematuria Using Computed Tomography |
https://ClinicalTrials.gov/show/NCT04077359 |
Recruiting |
Oslo University Hospital |
2021-09-01 |
| NCT04066595 |
Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. |
https://ClinicalTrials.gov/show/NCT04066595 |
Recruiting |
Johannes Gutenberg University Mainz |
2023-09-30 |
| NCT04047693 |
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT04047693 |
Recruiting |
Pusan National University Yangsan Hospital |
2021-12-31 |
| NCT04045613 |
Derazantinib and Atezolizumab in Patients With Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT04045613 |
Recruiting |
Basilea Pharmaceutica |
2022-04-30 |
| NCT04018053 |
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy |
https://ClinicalTrials.gov/show/NCT04018053 |
Recruiting |
Dana-Farber Cancer Institute |
2021-12-31 |
| NCT04007744 |
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04007744 |
Recruiting |
Mayo Clinic |
2021-07-31 |
| NCT04004442 |
Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT04004442 |
Recruiting |
University of Oklahoma |
2021-07-31 |
| NCT03992131 |
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) |
https://ClinicalTrials.gov/show/NCT03992131 |
Recruiting |
Clovis Oncology, Inc. |
2023-10-31 |
| NCT03980041 |
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) |
https://ClinicalTrials.gov/show/NCT03980041 |
Recruiting |
Infinity Pharmaceuticals, Inc. |
2020-11-30 |
| NCT03967977 |
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03967977 |
Recruiting |
BeiGene |
2022-07-31 |
| NCT03945084 |
Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy |
https://ClinicalTrials.gov/show/NCT03945084 |
Recruiting |
University of Turin, Italy |
2021-12-31 |
| NCT03917381 |
GEN1046 Safety Trial in Patients With Malignant Solid Tumors |
https://ClinicalTrials.gov/show/NCT03917381 |
Recruiting |
Genmab |
2021-10-31 |
| NCT03915405 |
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03915405 |
Recruiting |
Kyowa Kirin Pharmaceutical Development, Inc. |
2021-12-31 |
| NCT03914794 |
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors |
https://ClinicalTrials.gov/show/NCT03914794 |
Recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2022-05-31 |
| NCT03912818 |
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03912818 |
Recruiting |
Stanford University |
2022-02-13 |
| NCT03869190 |
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy |
https://ClinicalTrials.gov/show/NCT03869190 |
Recruiting |
Hoffmann-La Roche |
2020-09-30 |
| NCT03854721 |
A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03854721 |
Recruiting |
Vaxiion Therapeutics |
2020-11-30 |
| NCT03827837 |
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors |
https://ClinicalTrials.gov/show/NCT03827837 |
Recruiting |
Jiangsu HengRui Medicine Co., Ltd. |
2020-06-30 |
| NCT03809624 |
Study of INBRX-105 in Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT03809624 |
Recruiting |
Inhibrx, Inc. |
2021-07-31 |
| NCT03809013 |
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT03809013 |
Recruiting |
RemeGen |
2021-10-31 |
| NCT03758781 |
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03758781 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2021-02-28 |
| NCT03745911 |
Paclitaxel and TAK-228 in Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03745911 |
Recruiting |
Associació per a la Recerca Oncologica, Spain |
2020-11-30 |
| NCT03744793 |
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT03744793 |
Recruiting |
M.D. Anderson Cancer Center |
2021-01-31 |
| NCT03735680 |
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer |
https://ClinicalTrials.gov/show/NCT03735680 |
Recruiting |
OncoNano Medicine, Inc. |
2020-09-30 |
| NCT03689192 |
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03689192 |
Recruiting |
Herlev Hospital |
2020-12-31 |
| NCT03682289 |
Phase II Trial of AZD6738 Alone and in Combination With Olaparib |
https://ClinicalTrials.gov/show/NCT03682289 |
Recruiting |
University of California, San Francisco |
2021-03-19 |
| NCT03676946 |
A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03676946 |
Recruiting |
Lee’s Pharmaceutical Limited |
2020-02-14 |
| NCT03658304 |
Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03658304 |
Recruiting |
University of Florida |
2025-12-31 |
| NCT03641287 |
The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors |
https://ClinicalTrials.gov/show/NCT03641287 |
Recruiting |
University of Washington |
2020-10-24 |
| NCT03639714 |
A Study of a Personalized Neoantigen Cancer Vaccine |
https://ClinicalTrials.gov/show/NCT03639714 |
Recruiting |
Gritstone Oncology, Inc. |
2022-07-31 |
| NCT03633110 |
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine |
https://ClinicalTrials.gov/show/NCT03633110 |
Active, not recruiting |
Genocea Biosciences, Inc. |
2022-12-31 |
| NCT03617913 |
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03617913 |
Active, not recruiting |
Mayo Clinic |
2019-11-14 |
| NCT03617003 |
Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) |
https://ClinicalTrials.gov/show/NCT03617003 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-08-31 |
| NCT03609216 |
Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations |
https://ClinicalTrials.gov/show/NCT03609216 |
Recruiting |
Alliance for Clinical Trials in Oncology |
2027-02-28 |
| NCT03606174 |
Study of Sitravatinib and Nivolumab in Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03606174 |
Recruiting |
Mirati Therapeutics Inc. |
2021-01-31 |
| NCT03601455 |
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03601455 |
Recruiting |
Jonsson Comprehensive Cancer Center |
2021-11-01 |
| NCT03584659 |
Patient-reported Outcomes in Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03584659 |
Recruiting |
Rigshospitalet, Denmark |
2020-03-31 |
| NCT03582475 |
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate |
https://ClinicalTrials.gov/show/NCT03582475 |
Recruiting |
Jonsson Comprehensive Cancer Center |
2020-09-01 |
| NCT03575013 |
A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT03575013 |
Recruiting |
University of Iowa |
2021-02-28 |
| NCT03558503 |
The Efficacy and Safety of UGN-102 as a Primary Chemoablative Therapy in Patients With LG NMIBC at Intermediate Risk of Recurrence |
https://ClinicalTrials.gov/show/NCT03558503 |
Active, not recruiting |
UroGen Pharma Ltd. |
2019-12-04 |
| NCT03557918 |
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT03557918 |
Recruiting |
Hoosier Cancer Research Network |
2020-07-31 |
| NCT03549715 |
NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03549715 |
Recruiting |
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie |
2023-11-30 |
| NCT03534804 |
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03534804 |
Recruiting |
University of Utah |
2023-09-30 |
| NCT03523572 |
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT03523572 |
Recruiting |
Daiichi Sankyo, Inc. |
2020-09-30 |
| NCT03520231 |
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases |
https://ClinicalTrials.gov/show/NCT03520231 |
Recruiting |
University Health Network, Toronto |
2019-12-01 |
| NCT03513952 |
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03513952 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT03511391 |
CHEckpoint Inhibition in Combination With an Immunoboost of External Body Radiotherapy in Solid Tumors |
https://ClinicalTrials.gov/show/NCT03511391 |
Recruiting |
University Hospital, Ghent |
2022-02-14 |
| NCT03507166 |
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT03507166 |
Completed |
RemeGen |
2018-10-29 |
| NCT03486197 |
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03486197 |
Recruiting |
University of Washington |
2022-11-01 |
| NCT03473756 |
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03473756 |
Recruiting |
Bayer |
2024-03-18 |
| NCT03473743 |
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Locally Advanced Urothelial Cancer With Selected FGFR Gene Alterations |
https://ClinicalTrials.gov/show/NCT03473743 |
Recruiting |
Janssen Research & Development, LLC |
2021-06-17 |
| NCT03473730 |
Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer |
https://ClinicalTrials.gov/show/NCT03473730 |
Recruiting |
M.D. Anderson Cancer Center |
2021-12-31 |
| NCT03421652 |
Nivolumab and Radiation Therapy in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemotherapy |
https://ClinicalTrials.gov/show/NCT03421652 |
Recruiting |
Barbara Ann Karmanos Cancer Institute |
2021-01-31 |
| NCT01261728 |
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT01261728 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-12-31 |
| NCT01225887 |
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer |
https://ClinicalTrials.gov/show/NCT01225887 |
Completed |
Gynecologic Oncology Group |
2016-01-31 |
| NCT01191892 |
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer |
https://ClinicalTrials.gov/show/NCT01191892 |
Completed |
Cardiff University |
2015-12-31 |
| NCT01097746 |
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01097746 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-04-30 |
| NCT01093066 |
Prospective Multicentric Evaluation of a Bladder Preservation Strategy |
https://ClinicalTrials.gov/show/NCT01093066 |
Active, not recruiting |
Centre Hospitalier Universitaire de Saint Etienne |
2022-12-31 |
| NCT01090466 |
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium |
https://ClinicalTrials.gov/show/NCT01090466 |
Completed |
Cardiff University |
2010-01-31 |
| NCT01089088 |
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) |
https://ClinicalTrials.gov/show/NCT01089088 |
Completed |
Cardiff University |
2014-10-31 |
| NCT01074411 |
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01074411 |
Completed |
National Cancer Institute (NCI) |
2014-04-04 |
| NCT01031875 |
Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment |
https://ClinicalTrials.gov/show/NCT01031875 |
Completed |
National Cancer Institute (NCI) |
2011-12-31 |
| NCT01031420 |
Dose Dense MVAC for Muscle Invasive Bladder Cancer |
https://ClinicalTrials.gov/show/NCT01031420 |
Completed |
Fox Chase Cancer Center |
2013-07-19 |
| NCT00989651 |
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00989651 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-09-01 |
| NCT00963859 |
Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder |
https://ClinicalTrials.gov/show/NCT00963859 |
Completed |
M.D. Anderson Cancer Center |
2011-06-30 |
| NCT00942331 |
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00942331 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-11-02 |
| NCT00888173 |
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer |
https://ClinicalTrials.gov/show/NCT00888173 |
Completed |
Gynecologic Oncology Group |
2016-07-16 |
| NCT00880334 |
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC |
https://ClinicalTrials.gov/show/NCT00880334 |
Completed |
Dana-Farber Cancer Institute |
2013-12-31 |
| NCT03794102 |
Water Versus Saline as Irrigation Fluid for Ureteroscopy |
https://ClinicalTrials.gov/show/NCT03794102 |
Completed |
Emory University |
2017-12-22 |
| NCT02795156 |
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations |
https://ClinicalTrials.gov/show/NCT02795156 |
Recruiting |
SCRI Development Innovations, LLC |
2020-12-01 |
| NCT02599324 |
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors |
https://ClinicalTrials.gov/show/NCT02599324 |
Recruiting |
Pharmacyclics LLC. |
2022-04-30 |
| NCT00794950 |
Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT00794950 |
Completed |
University of Michigan |
2016-08-22 |
| NCT04003610 |
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) |
https://ClinicalTrials.gov/show/NCT04003610 |
Recruiting |
Incyte Corporation |
2022-11-30 |
| NCT03636256 |
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03636256 |
Recruiting |
NanOlogy, LLC |
2020-11-30 |
| NCT00808639 |
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT00808639 |
Completed |
Dana-Farber Cancer Institute |
2013-12-31 |
| NCT01828736 |
Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT01828736 |
Completed |
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie |
2010-02-23 |
| NCT00805129 |
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium |
https://ClinicalTrials.gov/show/NCT00805129 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-12-31 |
| NCT04073602 |
A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT04073602 |
Recruiting |
RemeGen |
2020-06-30 |
| NCT03062059 |
The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence |
https://ClinicalTrials.gov/show/NCT03062059 |
Recruiting |
National Cancer Center, Korea |
2021-12-31 |
| NCT02581982 |
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT02581982 |
Active, not recruiting |
Wake Forest University Health Sciences |
2020-12-31 |
| NCT03898180 |
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) |
https://ClinicalTrials.gov/show/NCT03898180 |
Recruiting |
Merck Sharp & Dohme Corp. |
2022-12-30 |
| NCT03866382 |
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
https://ClinicalTrials.gov/show/NCT03866382 |
Recruiting |
National Cancer Institute (NCI) |
2023-02-28 |
| NCT02365766 |
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects |
https://ClinicalTrials.gov/show/NCT02365766 |
Active, not recruiting |
Hoosier Cancer Research Network |
2020-07-31 |
| NCT03244384 |
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT03244384 |
Recruiting |
National Cancer Institute (NCI) |
2025-06-01 |
| NCT02834013 |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
https://ClinicalTrials.gov/show/NCT02834013 |
Recruiting |
National Cancer Institute (NCI) |
2021-08-31 |
| NCT04432857 |
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04432857 |
Recruiting |
Adlai Nortye Biopharma Co., Ltd. |
2022-12-31 |
| NCT02178241 |
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02178241 |
Completed |
National Cancer Institute (NCI) |
2019-03-18 |
| NCT04129606 |
Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy |
https://ClinicalTrials.gov/show/NCT04129606 |
Active, not recruiting |
Mansoura University |
2021-07-01 |
| NCT03529890 |
Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder |
https://ClinicalTrials.gov/show/NCT03529890 |
Recruiting |
Technische Universität München |
2022-02-28 |
| NCT00888615 |
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00888615 |
Completed |
Gynecologic Oncology Group |
2011-09-01 |
| NCT00792025 |
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer |
https://ClinicalTrials.gov/show/NCT00792025 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00790426 |
Phase II Study of TKI258 in Advanced Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT00790426 |
Completed |
Novartis |
2012-04-30 |
| NCT00749892 |
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT00749892 |
Completed |
M.D. Anderson Cancer Center |
2019-06-30 |
| NCT00734994 |
Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00734994 |
Completed |
Duke University |
2011-02-28 |
| NCT00722553 |
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder |
https://ClinicalTrials.gov/show/NCT00722553 |
Completed |
Acrotech Biopharma LLC |
2011-04-30 |
| NCT00719303 |
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00719303 |
Recruiting |
Gynecologic Oncology Group |
2020-12-31 |
| NCT00714025 |
A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy |
https://ClinicalTrials.gov/show/NCT00714025 |
Completed |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2009-04-30 |
| NCT00710970 |
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment |
https://ClinicalTrials.gov/show/NCT00710970 |
Completed |
Baylor College of Medicine |
2011-12-31 |
| NCT00706641 |
Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder |
https://ClinicalTrials.gov/show/NCT00706641 |
Completed |
Hoosier Cancer Research Network |
2012-12-31 |
| NCT00694798 |
Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder |
https://ClinicalTrials.gov/show/NCT00694798 |
Completed |
Cadila Pharnmaceuticals |
2011-07-31 |
| NCT00683059 |
Single Agent Abraxane as Second Line Therapy in Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00683059 |
Completed |
Sunnybrook Health Sciences Centre |
2012-06-30 |
| NCT00633789 |
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types |
https://ClinicalTrials.gov/show/NCT00633789 |
Completed |
Bristol-Myers Squibb |
2012-02-29 |
| NCT00623831 |
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen |
https://ClinicalTrials.gov/show/NCT00623831 |
Completed |
Ludwig Institute for Cancer Research |
2012-05-31 |
| NCT00623064 |
Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT00623064 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2012-06-30 |
| NCT00588666 |
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT00588666 |
Completed |
Memorial Sloan Kettering Cancer Center |
2011-12-31 |
| NCT00539773 |
Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder |
https://ClinicalTrials.gov/show/NCT00539773 |
Completed |
King Faisal Specialist Hospital & Research Center |
2013-09-30 |
| NCT00536588 |
A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816) |
https://ClinicalTrials.gov/show/NCT00536588 |
Completed |
Merck Sharp & Dohme Corp. |
2009-08-31 |
| NCT01167712 |
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01167712 |
Active, not recruiting |
National Cancer Institute (NCI) |
2015-12-01 |
| NCT00478361 |
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function |
https://ClinicalTrials.gov/show/NCT00478361 |
Completed |
M.D. Anderson Cancer Center |
2015-06-30 |
| NCT00471536 |
Pazopanib in Treating Patients With Metastatic Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT00471536 |
Completed |
National Cancer Institute (NCI) |
2010-07-31 |
| NCT00462488 |
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ |
https://ClinicalTrials.gov/show/NCT00462488 |
Completed |
Viventia Bio |
2009-10-31 |
| NCT00407485 |
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium |
https://ClinicalTrials.gov/show/NCT00407485 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00397488 |
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium |
https://ClinicalTrials.gov/show/NCT00397488 |
Completed |
Memorial Sloan Kettering Cancer Center |
2012-02-29 |
| NCT00389155 |
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy |
https://ClinicalTrials.gov/show/NCT00389155 |
Completed |
Bristol-Myers Squibb |
2008-01-31 |
| NCT00365157 |
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction |
https://ClinicalTrials.gov/show/NCT00365157 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT00362713 |
Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection |
https://ClinicalTrials.gov/show/NCT00362713 |
Completed |
Bristol-Myers Squibb |
2009-10-31 |
| NCT00343356 |
Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder |
https://ClinicalTrials.gov/show/NCT00343356 |
Completed |
LanZhou University |
NA |
| NCT00330499 |
Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. |
https://ClinicalTrials.gov/show/NCT00330499 |
Completed |
Trans-Tasman Radiation Oncology Group (TROG) |
2010-02-28 |
| NCT00315237 |
Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract |
https://ClinicalTrials.gov/show/NCT00315237 |
Completed |
Bristol-Myers Squibb |
2008-01-31 |
| NCT00310011 |
Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium |
https://ClinicalTrials.gov/show/NCT00310011 |
Completed |
Wake Forest University Health Sciences |
2005-10-31 |
| NCT00262847 |
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00262847 |
Completed |
National Cancer Institute (NCI) |
2010-11-30 |
| NCT00238420 |
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00238420 |
Active, not recruiting |
National Cancer Institute (NCI) |
2014-02-05 |
| NCT00191971 |
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen |
https://ClinicalTrials.gov/show/NCT00191971 |
Completed |
Eli Lilly and Company |
NA |
| NCT00173862 |
Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC |
https://ClinicalTrials.gov/show/NCT00173862 |
Completed |
National Taiwan University Hospital |
NA |
| NCT00154687 |
Weekly TP-HDFL in the Treatment of Advanced TCC |
https://ClinicalTrials.gov/show/NCT00154687 |
Completed |
National Taiwan University Hospital |
NA |
| NCT00112671 |
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract |
https://ClinicalTrials.gov/show/NCT00112671 |
Completed |
National Cancer Institute (NCI) |
2010-05-31 |
| NCT00108745 |
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00108745 |
Active, not recruiting |
Gynecologic Oncology Group |
2022-01-01 |
| NCT00101842 |
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00101842 |
Completed |
Eli Lilly and Company |
NA |
| NCT00101608 |
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium |
https://ClinicalTrials.gov/show/NCT00101608 |
Completed |
Bristol-Myers Squibb |
2007-04-30 |
| NCT00002914 |
Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract |
https://ClinicalTrials.gov/show/NCT00002914 |
Completed |
Eastern Cooperative Oncology Group |
2001-06-30 |
| NCT00003175 |
Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00003175 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00003133 |
Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00003133 |
Completed |
Memorial Sloan Kettering Cancer Center |
2003-01-31 |
| NCT00003376 |
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium |
https://ClinicalTrials.gov/show/NCT00003376 |
Completed |
Eastern Cooperative Oncology Group |
2005-09-30 |
| NCT00080795 |
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium |
https://ClinicalTrials.gov/show/NCT00080795 |
Completed |
M.D. Anderson Cancer Center |
2006-05-31 |
| NCT00006376 |
R115777 in Treating Patients With Advanced Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00006376 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00006026 |
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract |
https://ClinicalTrials.gov/show/NCT00006026 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2001-10-31 |
| NCT00004223 |
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00004223 |
Completed |
Eastern Cooperative Oncology Group |
2002-10-31 |
| NCT00077688 |
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium |
https://ClinicalTrials.gov/show/NCT00077688 |
Completed |
Achieve Life Sciences |
NA |
| NCT00004203 |
Oxaliplatin in Treating Patients With Metastatic Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00004203 |
Completed |
University of Chicago |
2002-02-28 |
| NCT00009867 |
Arsenic Trioxide in Treating Patients With Urothelial Cancer |
https://ClinicalTrials.gov/show/NCT00009867 |
Completed |
National Cancer Institute (NCI) |
2004-06-30 |
| NCT00003167 |
Gene Therapy in Treating Patients With Advanced Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00003167 |
Completed |
National Cancer Institute (NCI) |
2002-12-31 |
| NCT00072150 |
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT00072150 |
Completed |
National Cancer Institute (NCI) |
2006-03-31 |
| NCT00004074 |
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
https://ClinicalTrials.gov/show/NCT00004074 |
Completed |
National Cancer Institute (NCI) |
2009-02-28 |
| NCT00014144 |
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract |
https://ClinicalTrials.gov/show/NCT00014144 |
Completed |
Southwest Oncology Group |
2003-05-31 |
| NCT00021099 |
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00021099 |
Completed |
National Cancer Institute (NCI) |
2007-08-31 |
| NCT00066612 |
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy |
https://ClinicalTrials.gov/show/NCT00066612 |
Completed |
Southwest Oncology Group |
2007-08-31 |
| NCT00066352 |
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter |
https://ClinicalTrials.gov/show/NCT00066352 |
Completed |
University Health Network, Toronto |
2003-09-30 |
| NCT00053209 |
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium |
https://ClinicalTrials.gov/show/NCT00053209 |
Completed |
Eastern Cooperative Oncology Group |
2007-09-30 |
| NCT00045630 |
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium |
https://ClinicalTrials.gov/show/NCT00045630 |
Completed |
Southwest Oncology Group |
2008-05-31 |
| NCT00041106 |
Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00041106 |
Completed |
National Cancer Institute (NCI) |
2007-07-31 |
| NCT00028860 |
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00028860 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00028756 |
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium |
https://ClinicalTrials.gov/show/NCT00028756 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2014-01-31 |
| NCT00022191 |
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00022191 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2004-06-30 |
| NCT00014274 |
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium |
https://ClinicalTrials.gov/show/NCT00014274 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2008-03-31 |
| NCT00006351 |
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract |
https://ClinicalTrials.gov/show/NCT00006351 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2001-12-31 |
| NCT00005831 |
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00005831 |
Completed |
National Cancer Institute (NCI) |
2004-08-31 |
| NCT00005644 |
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function |
https://ClinicalTrials.gov/show/NCT00005644 |
Completed |
Eastern Cooperative Oncology Group |
2003-02-28 |
| NCT00003342 |
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00003342 |
Completed |
Memorial Sloan Kettering Cancer Center |
2007-07-31 |
| NCT00001381 |
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder |
https://ClinicalTrials.gov/show/NCT00001381 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00035061 |
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium |
https://ClinicalTrials.gov/show/NCT00035061 |
Completed |
Eli Lilly and Company |
NA |
| NCT00034593 |
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium |
https://ClinicalTrials.gov/show/NCT00034593 |
Completed |
Eli Lilly and Company |
NA |
| NCT00003105 |
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer |
https://ClinicalTrials.gov/show/NCT00003105 |
Completed |
Memorial Sloan Kettering Cancer Center |
2004-08-31 |